Emerald Health Pharmaceuticals Expands Global Technology Protection with the Granting of Six New International Patents
March 16, 2020 13:38 ET
|
Emerald Health Pharmaceuticals
New grants add to the strong core patents previously granted in the US, Europe and other countries SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc....
Emerald Health Pharmaceuticals Receives Fast Track Designation from US FDA for EHP-101 in the Treatment of Systemic Sclerosis
March 03, 2020 08:30 ET
|
Emerald Health Pharmaceuticals
First-in-class product candidate in Phase 2 clinical development now has Fast Track and Orphan designations SAN DIEGO, CA, March 03, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc....
Emerald Health Pharmaceuticals Presents Phase I Clinical Data and Preclinical Remyelination Data at ACTRIMS 2020 Conference
February 27, 2020 09:30 ET
|
Emerald Health Pharmaceuticals
Emerald’s lead product candidate, EHP-101, shows potential disease-modifying capabilities in multiple sclerosis, further supporting advancement into Phase II clinical development SAN DIEGO, CA, Feb. ...
Emerald Health Pharmaceuticals to Present at 2020 ACTRIMS Conference on Multiple Sclerosis
February 19, 2020 11:53 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage pharmaceutical company developing medicines based on cannabinoid science, has been...
Emerald Health Pharmaceuticals Granted Orphan Designation in Europe for Huntington’s Disease
January 29, 2020 10:46 ET
|
Emerald Health Pharmaceuticals
Follows the success of obtaining Orphan Drug Designation for Huntington’s Disease in the US SAN DIEGO, CA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a...
Emerald Health Pharmaceuticals Receives U.S. FDA Clearance of IND Application for Phase 2 Study of EHP-101 in Orphan Disease
January 13, 2020 09:30 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing medicines based on cannabinoid science, announced today...
Emerald Health Pharmaceuticals to Participate in Investment and Scientific Conferences in September
September 03, 2019 10:06 ET
|
Emerald Health Pharmaceuticals
SAN DIEGO, CA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that Jim...
Emerald Health Pharmaceuticals Completes First-In-Human Clinical Study of Novel Oral Treatment for Multiple Sclerosis and Systemic Scleroderma
August 26, 2019 08:30 ET
|
Emerald Health Pharmaceuticals
Phase I study of CBD-derived drug candidate demonstrates safety and tolerability in over 100 subjects Phase II studies planned to start before year-end SAN DIEGO, CA, Aug. 26, 2019 ...
Emerald Health Pharmaceuticals Demonstrates Repair of Nerve Damage Related to Multiple Sclerosis
July 02, 2019 09:00 ET
|
Emerald Health Pharmaceuticals
Preclinical data show remyelination with the clinical-stage drug product candidate, EHP-101 SAN DIEGO, CA, July 02, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a...
Emerald Health Pharmaceuticals Demonstrates Neuroprotective Activity of Novel Cannabigerol Derivatives in Huntington’s and Parkinson’s Disease Models
July 02, 2019 09:00 ET
|
Emerald Health Pharmaceuticals
EHP-102 and other novel cannabigerol derivatives from Emerald Health Pharmaceuticals demonstrate therapeutic potential in validated animal models SAN DIEGO, CA, July 02, 2019 (GLOBE NEWSWIRE)...